Просмотр новости
Найдите то, что Вас интересует
Спутники
РН
SpaceX
Роскосмос
NASA
СпутникиРНSpaceXРоскосмосNASATo the Editor I read with great interest the updated analysis of the SONIA trial by Wortelboer et al, which demonstrated that first-line use of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) did not improve overall survival (OS) compared with second-line use in hormone receptor–positive advanced breast cancer. This trial provides pivotal data challenging the paradigm of moving targeted therapies to earlier courses.
| # | Наименование новости | Тональность | Информативность | Дата публикации |
|---|---|---|---|---|
| 1 | Survival in the SONIA Trial | 0 | 7 | 18-06-2026 |
| 2 | Survival in the SONIA Trial—Reply | 0 | 5 | 18-06-2026 |
| 3 | Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2 -Positive Breast Cancer | 0 | 7 | 25-06-2026 |
| 4 | Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors | 0 | 7 | 25-06-2026 |
| 5 | Less Can Be More by Circulating Tumor DNA Use in ERBB2 -Positive Breast Cancer | 0 | 7 | 25-06-2026 |
| 6 | Team finds way to reverse ovarian cancer’s chemo resistance | 5 | 8 | 25-06-2026 |
| 7 | Single-Fraction Stereotactic Body Radiotherapy for Localized Prostate Cancer | 0 | 5 | 18-06-2026 |
| 8 | Second Primary Malignant Neoplasms After T-Cell–Engaging Bispecific Antibody Therapy | 0 | 7 | 18-06-2026 |
| 9 | Conn. Provider Must Share Takeover Data After $49M Verdict | 0 | 7 | 26-06-2026 |
| 10 | Three-Body Problem at Digital Frontiers | 0 | 5 | 25-06-2026 |